Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

Regular price $4,995.00 Sale

Published on May 27, 2014 - 116 pages

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and targeted therapies is radically altering the treatment algorithm. From Roche's improved anti-CD20 monoclonal antibody Gazyva, to Pharmacyclics/Janssen Biotech's Imbruvica, the treatment landscape is being transformed.

Drivers of change
  • Targeted therapies. Most significantly, KOLs predict that therapies from Roche, Gilead, Infinity and Pharmacyclics/Janssen Biotech will drive change in the refractory/relapsed setting for patients who are younger and fitter, and in the first- and second-line settings for frail patients or those with high-risk genetic markers.
  • Chemotherapy-free treatment. Combined with chlorambucil, Roche's Gazyva is expected to provide a first-line option for patients whose comorbidity burden precludes standard treatment. Further, the advent of Imbruvica and idelalisib (in combination with Rituxan) signals a move towards chemo-free therapy.
  • Personalised medicine approach. With the expansion of therapies and increased economic pressure, KOLs predict a move towards personalised treatments involving the combination of new oral therapies with other drugs. Molecular profiling may also evolve its role, since CLL's marked clinical and biological heterogeneity make it a prime target for individualised treatment.
Unique insider clinical opinion

Insightful, targeted and filled with critical knowledge, Chronic Lymphocytic Leukaemia: KOL Insight offers a 360deg view of current and future treatment pathways for CLL. Based on in-depth interviews with 13 KOLs from Europe and North America, the report focuses on existing and pipeline drugs, clinical trials and trends that are set to revolutionise the future of CLL treatment.Pressing issues and questions:
  • How are monoclonal antibodies perceived by the medical community in terms of efficacy, tolerability and ease of administration - and how do they compare to other options?
  • To what extent will Roche's Gazyva and the emergence of rituximab biosimilars threaten the dominance of Rituxan?
  • How will the use of each current and pipeline CLL product change in the future in terms of patient segments, line of therapy and preference?
  • How will the arrival of small molecule targeted therapies such as Imbruvica, idelalisib, ABT-199 and alvocidib impact the treatment and prognosis of patients with genetically-defined high-risk CLL?
Key Benefits

New drug therapies for CLL are about to revolutionise treatment regimens. In Chronic Lymphocytic Leukemia: KOL Insight, you will:
  • Understand the scope of major shifts in CLL treatments in the refractory/relapsed setting, led by Roche's Gazyva and the new oral targeted therapies
  • Gain a full overview of the potential impact on prescribing trends by recently completed and ongoing clinical trials, such as HELIOS, CLL 11, COMPLEMENT 1, RESONATE and RESONATE-2
  • Obtain insight into why KOLs view oral targeted therapies as potentially answering the unmet needs in the refractory-relapsed setting
  • Understand why new therapies and economic pressure will drive the movement towards individualised medicine
This report will allow you to:
  • Take a 360deg view of CLL treatments, both current and forthcoming
  • Analyse current and future treatment algorithms for patients with genetic high-risk markers, and high and low comorbidity burdens
  • Identify key trends that will impact future prescribing habits
  • Receive KOL opinion updates covering each major event between now and 31 May 2015
Selected KOL Views

"Imbruvica is going to completely change the management of CLL." EU Key Opinion Leader

"I believe rituximab will still be the king of kings of the treatment of CLL and of several other malignant lymphomas for the short term. I don't expect to see a significant decline [in the use of rituximab] with the introduction of ibrutinib or idelalisib, or any other new products, in the next five years." EU Key Opinion Leader

"The excellent results with Gazyva will change the landscape in treating CLL in my opinion. And so the role of rituximab generally will diminish." EU Key Opinion Leader

"It's Roche's strategy: 'so you have got a biosimilar to rituximab, but obinutuzumab is better'. If they can convince enough people of that, biosimilars may have some problems." North American Key Opinion Leader

"ABT-199 is a phenomenally-effective drug. It is distinguished by its ability to achieve marrow clearing complete responses. So that's pretty significant." North American Key Opinion Leader

KOL Panel

KOLs from North America:
  • Dr Steve Coutre, MD, Associate Professor Haematologist, Stanford Cancer Center, Stanford, CA, USA
  • Dr Bruce Cheson, MD, FACP, FAAS, Professor of Medicine, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington DC, USA
  • Prof Thomas Froehlich, Director (All Cancer Clinics), Southwestern Simmons Cancer Center, Dallas, TX USA
  • Dr Ajay Gopal, Washington-Seattle Cancer Care Alliance Seattle WA, USA
  • Dr Brian Leber, Haematologist, Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada
  • Requested Anonymous, Assistant Professor of Hematology in the Division of Medical Oncology at a large US academic medical center
KOLs from Europe:
  • Prof Michele Baccarani, Haematologist, Institute of Haematology and Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy
  • Prof Uwe Martens, MD Hematologist, SLK Kliniken Heilbronn GmbH, Heilbronn, Germany
  • Prof Fabrizio Pane, MD. Professor of Haematology, University Hospital - University Federico II, Naples, Italy
  • Prof Donal McLornan, Consultant Haematologist, Guy's & St Thomas' Hospitals, London, UK
  • Dr Christian Taverna, Haematologist-Oncologist, Hospital Munsterlingen, Munsterlingen, Switzerland
  • Dr Carsten Muller-Tidow, MD, Director of the Department of Haematology /Oncology at the University Hospital of Halle, Germany
  • Prof Stephen G O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Professor of Haematology, Newcastle University; Honorary Consultant Haematologist, Newcastle Hospitals NHS Foundation Trust, UK
Always up to date

The world of pharma is ever changing and executives must always be up-to-date with the latest developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with the latest insight offers a real commercial advantage.

Consider the benefits: